Stability of fetal hemoglobin levels in patients receiving metformin therapy

Recently, in vitro studies using progenitor-derived erythroid cells from normal individuals or sickle cell disease (SCD) patients, have identified metformin, an oral hypoglycemic drug, as a promising agent to increase fetal hemoglobin (HbF) levels.[1][1]–[3][2] The mechanisms through which